Dr. Gavin Oudit has dedicated his career to the advancement of cardiovascular medicine and knowledge thereof in provincial, national and international settings through his research, education and clinical practice. He has made novel discoveries and several have translated into clinical trials including recombinant human ACE2 for lung disease and key role of ACE2 in COVID-19. He is involved with national and international societies and organizations for the promotion of cardiac research and health including in vulnerable patient groups. His leadership in enhancing translational research and innovative clinical care is coupled with 297 peer-reviewed publications (total citations=22,332; h-index=78) and multiple media highlights.